The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 2.5 µg/ml.
Use a concentration of 2.5 µg/ml. 10ng/ml Warfarin produces 69% inhibition in a competitive ELISA employing ab123975
Use a concentration of 2.5 µg/ml. ab123975 is suitable for the development of immunoaffinity purification columns.
Warfarin, a synthetic derivative of coumarinan, is an anticoagulant medication used for the prophylaxis of thrombosis and embolism in many disorders. It was originally developed as a rat poison, and is still widely used as such, although warfarin-resistant rats are becoming more common.
Warfarin inhibits the effective synthesis of biologically active forms of the vitamin K-dependent clotting factors: II, VII, IX and X, as well as the regulatory factors protein C, protein S and protein Z. Other proteins not involved in blood clotting, such as osteocalcin, may also be affected.
The precursors of these factors require carboxylation of their glutamic acid residues to allow the coagulation factors to bind to phospholipid surfaces. This carboxylation is linked to oxidation of vitamin K to form Vitamin K epoxide, which is in turn recycled back to the reduced form by the enzyme epoxide reductase. Warfarin inhibits epoxide reductase, thereby diminishing vitamin K action and inhibiting production of functioning coagulation factors. As the body's stores of previously-produced factors degrade (over several days), the anticoagulation effect becomes apparent. The coagulation factors are produced, but have decreased functionality due to undercarboxylation; they are collectively referred to as PIVKAs (proteins induced [by] vitamin K absence/antagonism).
Anti-Warfarin antibody (ab123975)参考文献
has not yet been referenced specifically in any publications.